Skip to main content
Erschienen in: European Radiology 12/2022

27.06.2022 | Hepatobiliary-Pancreas

Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas

verfasst von: Hai-Yan Chen, Yao Pan, Jie-Yu Chen, Lu-lu Liu, Yong-Bo Yang, Kai Li, Ri-Sheng Yu, Guo-Liang Shao

Erschienen in: European Radiology | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify quantitative CT features for distinguishing well-differentiated pancreatic neuroendocrine tumors (PNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PNECs).

Materials and methods

Seventeen patients with PNECs and 131 patients with PNETs confirmed by biopsy or surgery were retrospectively included. General demographic (sex, age) and CT quantitative parameters (arterial/portal absolute enhancement, arterial/portal relative enhancement ratio, arterial/portal enhancement ratio) were collected. Univariate and multivariate logistic regression analyses were performed to confirm independent variables for differentiating PNECs from PNETs. Receiver operating characteristic (ROC) curves for each quantitative parameter were generated to determine their diagnostic ability.

Results

PNECs had a much lower mean arterial/portal absolute enhancement value (19.5 ± 11.0 vs. 78.8 ± 47.2; 28.1 ± 15.8 vs. 77.0 ± 39.4), arterial/portal relative enhancement ratio (0.57 ± 0.36 vs. 2.03 ± 1.31; 0.80 ± 0.52 vs. 1.99 ± 1.13), and arterial/portal enhancement ratio (0.62 ± 0.27 vs. 1.22 ± 0.49; 0.74 ± 0.19 vs. 1.21 ± 0.36) than PNETs (all p < 0.001). After multivariable analysis, arterial absolute enhancement (odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.93, 0.99) and portal absolute enhancement (OR: 0.96, 95% CI: 0.92, 0.99) were independent factors for differentiating PNECs from PNETs. For each quantitative parameter, arterial lesion enhancement yielded the highest diagnostic performance, with an area under the curve (AUC) of 0.922 (95% CI: 0.867–0.960), followed by portal absolute enhancement.

Conclusions

Arterial/portal absolute enhancements were independent predictors with good diagnostic accuracy for differentiating between PNETs and PNECs. Quantitative parameters of enhanced CT can distinguish PNECs from PNETs.

Key Points

• PNECs were hypovascular and had a much lower enhanced CT attenuation in both arterial and portal phases than well-differentiated PNETs.
• Quantitative parameters derived from enhanced CT can be used to distinguish PNECs from PNETs.
• Arterial absolute enhancement and portal absolute enhancement were independent predictive factors for differentiating between PNETs and PNECs.
Literatur
1.
Zurück zum Zitat Ma ZY, Gong YF, Zhuang HK et al (2020) Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol 26:2305–2322CrossRefPubMedPubMedCentral Ma ZY, Gong YF, Zhuang HK et al (2020) Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol 26:2305–2322CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 68:471–487CrossRefPubMed Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 68:471–487CrossRefPubMed
3.
Zurück zum Zitat Choe J, Kim KW, Kim HJ et al (2019) What is new in the 2017 World Health Organization classification and 8th American Joint Committee on Cancer Staging System for pancreatic neuroendocrine neoplasms? Korean J Radiol 20:5–17CrossRefPubMed Choe J, Kim KW, Kim HJ et al (2019) What is new in the 2017 World Health Organization classification and 8th American Joint Committee on Cancer Staging System for pancreatic neuroendocrine neoplasms? Korean J Radiol 20:5–17CrossRefPubMed
4.
Zurück zum Zitat Bosman F, Carneiro F, Hruban RH, Theise ND (2010) World Health Organization classification of tumours of the digestive system. IARC Press, Lyon, France, pp 13–14 Bosman F, Carneiro F, Hruban RH, Theise ND (2010) World Health Organization classification of tumours of the digestive system. IARC Press, Lyon, France, pp 13–14
5.
Zurück zum Zitat Perren A, Couvelard A, Scoazec JY et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105:196–200CrossRefPubMed Perren A, Couvelard A, Scoazec JY et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105:196–200CrossRefPubMed
6.
Zurück zum Zitat Lloyd RV, Osamura RY, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs. WHO/ IARC Classification of Tumours. 4th ed. Vol 10. IARC Press, Lyon, France Lloyd RV, Osamura RY, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs. WHO/ IARC Classification of Tumours. 4th ed. Vol 10. IARC Press, Lyon, France
7.
Zurück zum Zitat Kim JY, Hong SM, Ro JY (2017) Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 29:11–16CrossRefPubMed Kim JY, Hong SM, Ro JY (2017) Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 29:11–16CrossRefPubMed
8.
Zurück zum Zitat Luo G, Javed A, Strosberg JR et al (2017) Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol 35:274–280CrossRefPubMed Luo G, Javed A, Strosberg JR et al (2017) Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol 35:274–280CrossRefPubMed
9.
Zurück zum Zitat Guilmette JM, Nosé V (2019) Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol 26:13–30CrossRefPubMed Guilmette JM, Nosé V (2019) Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol 26:13–30CrossRefPubMed
10.
Zurück zum Zitat Yang B, Chen HY, Zhang XY, Pan Y, Lu YF, Yu RS (2020) The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors. Eur J Radiol 124:108847CrossRefPubMed Yang B, Chen HY, Zhang XY, Pan Y, Lu YF, Yu RS (2020) The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors. Eur J Radiol 124:108847CrossRefPubMed
11.
Zurück zum Zitat Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI (2016) Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26:1338–1347CrossRefPubMed Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI (2016) Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26:1338–1347CrossRefPubMed
12.
Zurück zum Zitat Kim DW, Kim HJ, Kim KW et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRefPubMed Kim DW, Kim HJ, Kim KW et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRefPubMed
13.
Zurück zum Zitat Karmazanovsky G, Belousova E, Schima W, Glotov A, Kalinin D, Kriger A (2019) Nonhypervascular pancreatic neuroendocrine tumors: spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma. Eur J Radiol 110:66–73CrossRefPubMed Karmazanovsky G, Belousova E, Schima W, Glotov A, Kalinin D, Kriger A (2019) Nonhypervascular pancreatic neuroendocrine tumors: spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma. Eur J Radiol 110:66–73CrossRefPubMed
14.
Zurück zum Zitat Park HJ, Kim HJ, Kim KW et al (2020) Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol 30:4772–4782CrossRefPubMed Park HJ, Kim HJ, Kim KW et al (2020) Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol 30:4772–4782CrossRefPubMed
15.
Zurück zum Zitat Nagayama Y, Inoue T, Kato Y et al (2021) Relative enhancement ratio of portal venous phase to unenhanced CT in the diagnosis of lipid-poor adrenal adenomas. Radiology 301:360–368CrossRefPubMed Nagayama Y, Inoue T, Kato Y et al (2021) Relative enhancement ratio of portal venous phase to unenhanced CT in the diagnosis of lipid-poor adrenal adenomas. Radiology 301:360–368CrossRefPubMed
16.
Zurück zum Zitat Kim DW, Kim HJ, Kim KW et al (2016) Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients. Eur Radiol 26:1320–1329CrossRefPubMed Kim DW, Kim HJ, Kim KW et al (2016) Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients. Eur Radiol 26:1320–1329CrossRefPubMed
17.
Zurück zum Zitat Chen H-Y, Deng X-Y, Pan Y et al (2021) Pancreatic serous cystic neoplasms and mucinous cystic neoplasms: differential diagnosis by combining imaging features and enhanced CT texture analysis. Front Oncol 11:745001CrossRefPubMedPubMedCentral Chen H-Y, Deng X-Y, Pan Y et al (2021) Pancreatic serous cystic neoplasms and mucinous cystic neoplasms: differential diagnosis by combining imaging features and enhanced CT texture analysis. Front Oncol 11:745001CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Fang JM, Shi J (2019) A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the new World Health Organization classification. Arch Pathol Lab Med 143:1317–1326CrossRefPubMedPubMedCentral Fang JM, Shi J (2019) A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the new World Health Organization classification. Arch Pathol Lab Med 143:1317–1326CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lam AK, Ishida H (2021) Pancreatic neuroendocrine neoplasms: clinicopathological features and pathological staging. Histol Histopathol 36:367–382PubMed Lam AK, Ishida H (2021) Pancreatic neuroendocrine neoplasms: clinicopathological features and pathological staging. Histol Histopathol 36:367–382PubMed
20.
Zurück zum Zitat Chen H-Y, Zhang X-Y, Deng X-Y et al (2020) Grade 3 pancreatic neuroendocrine tumors on MDCT: establishing a diagnostic model and comparing survival against pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 215:1–8 Chen H-Y, Zhang X-Y, Deng X-Y et al (2020) Grade 3 pancreatic neuroendocrine tumors on MDCT: establishing a diagnostic model and comparing survival against pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 215:1–8
21.
Zurück zum Zitat Bian Y, Jiang H, Ma C et al (2020) CT-based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol 215:852–863 Bian Y, Jiang H, Ma C et al (2020) CT-based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol 215:852–863
22.
Zurück zum Zitat Azoulay A, Cros J, Vullierme MP et al (2020) Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma. Diagn Interv Imaging 101:821–830CrossRefPubMed Azoulay A, Cros J, Vullierme MP et al (2020) Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma. Diagn Interv Imaging 101:821–830CrossRefPubMed
23.
Zurück zum Zitat Xue Y, Reid MD, Pehlivanoglu B et al (2020) Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification. Endocr Pathol 31:239–253CrossRefPubMed Xue Y, Reid MD, Pehlivanoglu B et al (2020) Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification. Endocr Pathol 31:239–253CrossRefPubMed
24.
Zurück zum Zitat Singhi AD, Klimstra DS (2018) Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology 72:168–177CrossRefPubMed Singhi AD, Klimstra DS (2018) Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology 72:168–177CrossRefPubMed
26.
Zurück zum Zitat Liang W, Yang P, Huang R et al (2019) A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res 25:584–594CrossRefPubMed Liang W, Yang P, Huang R et al (2019) A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res 25:584–594CrossRefPubMed
27.
Zurück zum Zitat Loi S, Mori M, Benedetti G et al (2020) Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. Phys Med 76:125–133CrossRefPubMed Loi S, Mori M, Benedetti G et al (2020) Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. Phys Med 76:125–133CrossRefPubMed
Metadaten
Titel
Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas
verfasst von
Hai-Yan Chen
Yao Pan
Jie-Yu Chen
Lu-lu Liu
Yong-Bo Yang
Kai Li
Ri-Sheng Yu
Guo-Liang Shao
Publikationsdatum
27.06.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 12/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08891-4

Weitere Artikel der Ausgabe 12/2022

European Radiology 12/2022 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.